AC 1204

Drug Profile

AC 1204

Alternative Names: AC-1204

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Accera
  • Class Antidementias; Triglycerides
  • Mechanism of Action Glucose stimulants; Ketone body stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 11 Jul 2017 AC 1204 licensed to DuChemBio in South Korea
  • 14 Apr 2017 Accera completes a phase II/III trial for Alzheimer's disease in USA (PO) (NCT01741194)
  • 01 Apr 2017 Accera completes a phase I trial in Healthy male volunteers in USA (PO) (NCT02959710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top